Anand Mandaliya

Anand Mandaliya has extensive experience in strategic pricing and market access within the pharmaceutical sector, currently serving as Head of US Gross-to-Net Transformation at Amgen since May 2015. Anand has held multiple leadership roles at Amgen, including Chief of Staff for US Market Access and various director and managerial positions in Strategic Pricing & Contracting. Prior to Amgen, Anand worked as Pricing Lead for OptumRx at UnitedHealth Group and held positions in risk management at Sumitomo Corporation of Americas, as well as investment banking roles at Mid-Market Securities and CEA Group. Anand holds an MBA in Finance from Pepperdine Graziadio Business School and a BS in Finance from the University of Florida.